Charles Schwab Investment Management Inc. raised its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,440,294 shares of the biotechnology company's stock after acquiring an additional 38,761 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.03% of ADMA Biologics worth $41,851,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the third quarter worth about $31,000. GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares during the period. National Bank of Canada FI purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at approximately $35,000. Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at $62,000. Finally, Jones Financial Companies Lllp boosted its holdings in ADMA Biologics by 303.4% during the fourth quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock worth $98,000 after buying an additional 4,312 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.
Read Our Latest Report on ADMA
ADMA Biologics Price Performance
Shares of ADMA Biologics stock traded up $1.67 on Wednesday, reaching $20.38. The company's stock had a trading volume of 3,545,739 shares, compared to its average volume of 3,325,722. ADMA Biologics, Inc. has a 52-week low of $5.88 and a 52-week high of $23.64. The company has a market capitalization of $4.82 billion, a P/E ratio of 72.71 and a beta of 0.60. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $16.67 and a 200-day moving average price of $17.98.
ADMA Biologics Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
